New Stock News | Jiangxi Biopharmaceutical IPO prospectus invalid

11:09 27/04/2026

Jiangxi Biological Products Research Institute Co., Ltd. (hereinafter referred to as "Jiangxi Biological") submitted its Hong Kong IPO prospectus on October 26, 2025, which expired after 6 months on April 26, 2026. China International Capital Corporation and CMB International Securities acted as its joint sponsors at the time of submission.

Jiangxi Biological Products Research Institute Co., Ltd. (hereinafter referred to as "Jiangxi Biological") submitted a Hong Kong stock prospectus on October 26, 2025, which expired on April 26, 2026, after being valid for 6 months. CICC and CMSC International were its joint sponsors when submitting the application. According to the prospectus, Jiangxi Biological is the largest provider and exporter of tetanus antitoxin for human use ("human TAT") in China, and it is also a comprehensive anti-serum platform with an integrated industry chain.

US Stock Market Move | UBS Group AG (UBS.US) rose more than 3% in the first quarter, with a year-on-year net profit increase of 80%. The company plans to further buy back shares before the end of the year.

LINK HOLDINGS (08237): The joint liquidators have informed that the forced sale has been completed.

MINERVA GROUP (00397) plans to conduct a rights issue on a basis of "2 shares for every 1 share held".

LINK HOLDINGS (08237): The joint liquidators have informed that the forced sale has been completed.

MINERVA GROUP (00397) plans to conduct a rights issue on a basis of "2 shares for every 1 share held".